Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent and are willing to comply with protocol requirements~* Are 40 years of age or older.~* Are being evaluated for possible ACS.~* If female, then not of childbearing potential as documented by history or has a negative serum or urine pregnancy test within 4 hours prior to receiving the test drug and agrees to use an acceptable form of birth control.~Exclusion Criteria:~* \<40 years of age.~* Females who are pregnant or lactating.~* History of left ventricular ejection fraction (LVEF)=40%.~* History of MI.~* Acute ST segment elevation on ECG.~* Left bundle branch block on ECG.~* Known history of significant allergy to x-ray contrast media or iodine/iodides.~* Currently or formerly on medication that targets fatty acid uptake or metabolism, eg ranolazine, (Ranexa).~* Administered radiopharmaceutical other than rubidium-82 or thallium-201 within 2 days prior to study enrollment.~* Underwent cardiac stress testing of any kind within 2 days prior to study enrollment.~* Serum creatinine level \>2.0 mg per dL.~* Received investigational compound and/or medical device within 30 days of admission into this study.~* Q-wave abnormalities consistent with previous MI

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iodofiltic Acid I 123 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).